Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide (LY3305677) in obesity or overweight
NCT05623839Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing Mazdutide with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Related to Study Drug at 20 weeks. Started Nov 2022; status: completed.
02
Drugs
mazdutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05623839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623839.